UC-Davis Spinout Arete Begins Phase II Trials for Diabetes Rx with Entomology Underpinnings

If the drug reaches the market, likely through a partnership with a pharma, UC Davis stands to receive a "modest" royalty based on sales of the drug as part of an exclusive licensing agreement it signed with Arete.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.